Day One price target lowered to $26 from $30 at JonesResearch

JonesResearch lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $26 from $30 and keeps a Buy rating on the shares following the Q1 report. The company attributed the dip in revenue versus Q4 to seasonality in January, with fewer scans and appointments in the holiday season, which caused fewer patient starts, but has since recovered over the quarter, the analyst tells investors in a research note. Jones expects more consistent growth and penetration with Ojemda throughout 2025. It sees a “clear buying opportunity” in the stock for investors with at least a 12 month holding period.